Antifibrotic effects of oxetanyl sulfoxides

Description:

Currently, there are only two approved therapies for Idiopathic Pulmonary Fibrosis (IPF), pirfenidone and nintedanib, which are minimally effective at slowing the disease. These treatments are not effective at all in halting or reversing the progression of IPF. Therefore, there remains a great need for more effective therapies. Researchers at MUSC and Pitt have found that a novel compound, MMS-350, can significantly reduce pro-fibrotic factors and ECM proteins both in vitro and in vivo. Figure 1 demonstrates that in bleomycin treated mice oral doses of MMS-350 ameliorates fibrosis histologically (A), quantitatively reduces collagen α2I within 5 days of treatment (3B),  results in a large reduction of hydroxyproline levels (3C), reduces weight loss and increases survival (87.5% vs 62.5%). MMS-350 is also useful in preventing, mitigating and/or treating injury caused by radiation exposure.

Overview: The pulmonary fibrosis market in the US and EU is projected to be worth more than $1.1B in 2017. A successful pulmonary fibrosis treatment could likely be applied to additional fibrosis diseases, including kidney and liver due to similar disease mechanisms. The hallmark of pulmonary fibrosis is thickening and scarring of the tissue caused by increased deposition of extracellular matrix (ECM) proteins such as collagen and fibronectin. Fibrosis is the final stage of many diseases such as IPF, liver cirrhosis, and certain autoimmune disorders.  Scarring causes irreversible damage that usually leads to low quality of life, transplantation or death. 

 

Applications: Treatment of idiopathic pulmonary fibrosis, treatment of fibroproliferative disorders and systemic sclerosis, treatment or prophylactic for radiation induced damage

Advantages:  Low toxicity, oral bioavailability, high solubility, treat and decrease fibrosis, radioprotector, radiomitigator

Key Words: Fibrosis, scleroderma, IPF, MMS-350, bis-oxetanyl sulfoxide, bleomycin, autoimmune

 

Inventors: Carol Feghali-Bostwick and Peter Wipf       

Patent Status: US Patent US 9,676,738 and Divisional US 15/499,535       

MUSC-FRD Technology ID: P1641       

 

Patent Information:
Category(s):
Therapeutic
For Information, Contact:
Scott Davis
Sr Licensing Manager
MUSC Foundation for Research Development
843-876-1900
davissco@musc.edu
Inventors:
Carol Feghali-Bostwick
Peter Wipf
Keywords:
© 2017. All Rights Reserved. Powered by Inteum